The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma

Notwithstanding current multimodal treatment, including surgery, radiotherapy and chemotherapy with temozolomide (TMZ), median survival of glioblastoma (GBM) patients is about 14 months, due to the rapid emergence of cell clones resistant to treatment. Therefore, understanding the mechanisms underly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cell Cycle
Hauptverfasser: Banelli, Barbara, Carra, Elisa, Barbieri, Federica, Würth, Roberto, Parodi, Federica, Pattarozzi, Alessandra, Carosio, Roberta, Forlani, Alessandra, Allemanni, Giorgio, Marubbi, Daniela, Florio, Tullio, Daga, Antonio, Romani, Massimo
Format: Artigo
Sprache:Inglês
Veröffentlicht: Taylor & Francis 2015
Schlagworte:
Report
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4825557/
https://ncbi.nlm.nih.gov/pubmed/26566863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2015.1090063
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge